Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection

Mark M Painter^{1

2

3}, Timothy S Johnston^{1

4

5}, Kendall A Lundgreen⁶, Jefferson J S Santos⁶, Juliana S Qin³, Rishi R Goel^{1

2

3}, Sokratis A Apostolidis^{1

2

3

7}, Divij Mathew^{1

2}, Bria Fulmer^{1

2}, Justine C Williams³, Michelle L McKeague³, Ajinkya Pattekar³, Ahmad Goode³, Sean Nasta³, Amy E Baxter^{1

2}, Josephine R Giles^{1

2

8}, Ashwin N Skelly^{1

9}, Laura E Felley¹⁰, Maura McLaughlin^{1

2}, Joellen Weaver¹¹; Penn Medicine BioBank; Oliva Kuthuru^{1

2}, Jeanette Dougherty³, Sharon Adamski³, Sherea Long³, Macy Kee³, Cynthia Clendenin³, Ricardo da Silva Antunes¹², Alba Grifoni¹², Daniela Weiskopf¹², Alessandro Sette^{12

13}, Alexander C Huang^{1

8

14}, Daniel J Rader^{11

15}, Scott E Hensley⁶, Paul Bates⁶, Allison R Greenplate^{1

2

3}, E John Wherry^{16

17

18

19}

Collaborators, Affiliations

Collaborators

Affiliations

¹ Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
² Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
³ Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
⁴ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
⁵ Immunology Graduate Group, University of Pennsylvania, Philadelphia, PA, USA.
⁶ Department of Microbiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
⁷ Division of Rheumatology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
⁸ Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
⁹ Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
¹⁰ Division of Infectious Disease, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
¹¹ Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
¹² Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.
¹³ Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA.
¹⁴ Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
¹⁵ Penn Medicine Biobank, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
¹⁶ Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.
¹⁷ Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.
¹⁸ Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.
¹⁹ Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.

PMID: 37735592
DOI: 10.1038/s41590-023-01613-y

Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection

Mark M Painter et al. Nat Immunol. 2023 Oct.

. 2023 Oct;24(10):1711-1724.

doi: 10.1038/s41590-023-01613-y. Epub 2023 Sep 21.

Authors

Collaborators

Affiliations

¹ Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
² Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
³ Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
⁴ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
⁵ Immunology Graduate Group, University of Pennsylvania, Philadelphia, PA, USA.
⁶ Department of Microbiology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
⁷ Division of Rheumatology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
⁸ Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
⁹ Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
¹⁰ Division of Infectious Disease, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
¹¹ Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
¹² Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.
¹³ Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA.
¹⁴ Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
¹⁵ Penn Medicine Biobank, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
¹⁶ Institute for Immunology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.
¹⁷ Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.
¹⁸ Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.
¹⁹ Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.

PMID: 37735592
DOI: 10.1038/s41590-023-01613-y

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of vaccinated individuals is increasingly common but rarely results in severe disease, likely due to the enhanced potency and accelerated kinetics of memory immune responses. However, there have been few opportunities to rigorously study early recall responses during human viral infection. To better understand human immune memory and identify potential mediators of lasting vaccine efficacy, we used high-dimensional flow cytometry and SARS-CoV-2 antigen probes to examine immune responses in longitudinal samples from vaccinated individuals infected during the Omicron wave. These studies revealed heightened spike-specific responses during infection of vaccinated compared to unvaccinated individuals. Spike-specific cluster of differentiation (CD)4 T cells and plasmablasts expanded and CD8 T cells were robustly activated during the first week. In contrast, memory B cell activation, neutralizing antibody production and primary responses to nonspike antigens occurred during the second week. Collectively, these data demonstrate the functionality of vaccine-primed immune memory and highlight memory T cells as rapid responders during SARS-CoV-2 infection.

PubMed Disclaimer

Update of

Prior vaccination enhances immune responses during SARS-CoV-2 breakthrough infection with early activation of memory T cells followed by production of potent neutralizing antibodies.
Painter MM, Johnston TS, Lundgreen KA, Santos JJS, Qin JS, Goel RR, Apostolidis SA, Mathew D, Fulmer B, Williams JC, McKeague ML, Pattekar A, Goode A, Nasta S, Baxter AE, Giles JR, Skelly AN, Felley LE, McLaughlin M, Weaver J; Penn Medicine BioBank; Kuthuru O, Dougherty J, Adamski S, Long S, Kee M, Clendenin C, da Silva Antunes R, Grifoni A, Weiskopf D, Sette A, Huang AC, Rader DJ, Hensley SE, Bates P, Greenplate AR, Wherry EJ. Painter MM, et al. bioRxiv [Preprint]. 2023 Feb 6:2023.02.05.527215. doi: 10.1101/2023.02.05.527215. bioRxiv. 2023. Update in: Nat Immunol. 2023 Oct;24(10):1711-1724. doi: 10.1038/s41590-023-01613-y. PMID: 36798171 Free PMC article. Updated. Preprint.

References

1. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021). - PubMed
1. Addetia, A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J. Clin. Microbiol. 58, e02107-20 (2020). - PubMed - PMC
1. Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022). - PubMed
1. Andrews, N. et al. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532–1546 (2022). - PubMed
1. Canetti, M. et al. Six-month follow-up after a fourth BNT162b2 vaccine dose. N. Engl. J. Med. 387, 2092–2094 (2022). - PubMed

Grants and funding

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection

Collaborators

Affiliations

Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection

Authors

Collaborators

Affiliations

Abstract

Update of

References

Grants and funding

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous